0.0000 (0.0000%)
  • Bid / Lots
    10.6200/ 5
  • Ask / Lots
    13.5000/ 1
  • Open / Previous Close
    0.0000 / 11.8450
  • Day Range
  • 52 Week Range
    Low 3.7200
    High 17.5100
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 11.5
09:32 ET147811.16
09:45 ET210011.31
09:48 ET10011.41
09:50 ET40011.43
09:52 ET60011.5
09:54 ET10011.47
09:56 ET52711.43
09:57 ET40011.52
09:59 ET58511.44
10:01 ET28411.62
10:03 ET20011.49
10:06 ET30011.56
10:08 ET41811.54
10:35 ET10011.76
10:44 ET10011.58
11:08 ET10011.76
11:29 ET10011.77
11:33 ET10011.81
11:44 ET20011.63
11:51 ET20011.63
12:43 ET20011.74
01:01 ET10011.73
01:06 ET10011.64
01:21 ET10011.745
01:37 ET10011.74
02:00 ET20011.71
02:04 ET10011.83
02:27 ET10011.8
02:45 ET10011.8
02:47 ET10011.645
02:51 ET60111.725
03:03 ET10011.81
03:20 ET90011.95
03:30 ET10011.825
03:32 ET10011.825
03:34 ET18911.69
03:43 ET50011.825
03:45 ET10011.95
03:50 ET10012.015
03:52 ET20012.13
03:56 ET30012
03:57 ET20012.07
03:59 ET1283811.845
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPEPG
PepGen Inc
United StatesCRBP
Corbus Pharmaceuticals Holdings Inc
United StatesANL
Adlai Nortye Ltd
United StatesLXEO
Lexeo Therapeutics Inc
United StatesANNX
Annexon Inc
United StatesBMEA
Biomea Fusion Inc
As of 2024-04-19

Company Information

PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Contact Information

245 Main St, 2nd FloorCAMBRIDGE, MA, United States 02142


Independent Chairman of the Board
Laurie Keating
President, Chief Executive Officer, Treasurer, Secretary, Director
James Mcarthur
Chief Financial Officer
Noel Donnelly
Executive Vice President - Research and Preclinical Development
Jaya Goyal
Senior Vice President - Clinical Development
Michelle Mellion

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.